Institutional Biotech Investment Surge
Eagle Health Expands Biotech Portfolio With Significant Stakes in Kymera and Scholar Rock
Key Points
Osaic Holdings Inc. lifted its Kymera Therapeutics stake by 18,050.0% during the second quarter, now owning 1,089 shares worth about $48,000 after purchasing an additional 1,083 shares.
Merck & Co. Inc. acquired a new position in Kymera Therapeutics during the second quarter, worth about $88,544,161,000, according to HoldingsChannel.
BlackRock Inc. purchased a new stake in Kymera Therapeutics in the second quarter, valued at about $635,067,000.
Insider Stephen Michael Kelsey sold 4,175 shares of Revolution Medicines in a June 16 transaction at an average price of $156.12, reducing his direct stake to 291,876 shares worth about $45.57 million.
Scholar Rock Holding Corp (SRRK) is highly institutionally owned (about 91.08%), with Eagle Health’s new 555,272-share stake valued at roughly $30.54 million; the stock opened at $56.51 and has a 52-week range of $27.07 to $58.49.
Eagle Health Investments LP made aggressive moves into the biotech sector in the second quarter, purchasing 166,148 shares of Kymera Therapeutics (KYMR) worth approximately $19.05 million, according to WatchlistNews. The stake makes Kymera roughly 3.2% of Eagle Health's overall portfolio and ranks as its 14th largest position, signaling a strategic bet on the late-stage drug developer.
Eagle Health's Kymera purchase was part of a broader investment blitz across multiple biotech companies in Q2, according to TickerReport. The firm also bought 555,272 shares of Scholar Rock Holding for $30.54 million, 248,322 shares of Protagonist Therapeutics for $30.44 million, and 120,346 shares of Revolution Medicines for $22.54 million, demonstrating a diversified approach to biotech exposure.
Kymera Attracts Major Institutional Money
Kymera Therapeutics drew heavy interest from major investors beyond Eagle Health in the second quarter. BlackRock Inc. purchased a new stake valued at approximately $635 million, while Merck & Co. established a new position worth roughly $88.5 million, according to HoldingsChannel. These large purchases underscore institutional confidence in Kymera's pipeline and market position.
Scholar Rock Becomes 5% of Eagle Health's Portfolio
Scholar Rock Holding emerged as one of Eagle Health's most significant Q2 positions. The 555,272-share stake valued at $30.54 million represents 5.1% of the firm's total portfolio, according to TickerReport. Scholar Rock enjoys strong institutional backing with about 91.08% of shares held by institutions, and the stock trades in a 52-week range of $27.07 to $58.49.
Revolution Medicines Insider Sells While Institutions Buy
Revolution Medicines saw mixed activity in June as an insider reduced his stake while institutional investors expanded theirs. Stephen Michael Kelsey sold 4,175 shares on June 16 at an average price of $156.12, lowering his direct position to 291,876 shares worth $45.57 million. His sale came even as Eagle Health was purchasing 120,346 shares of the company for $22.54 million.
Eagle Health's Diversified Biotech Strategy
Eagle Health's Q2 purchases reveal a deliberate strategy to build stakes across multiple late-stage biotech names simultaneously. Beyond Kymera, Scholar Rock, Protagonist, and Revolution Medicines, the firm also bought 131,344 shares of Dianthus Therapeutics, making it its 20th largest position, according to TickerReport. This multi-name approach spreads risk while capturing gains from several clinical-stage drug developers moving toward potential approval.
Sentiment
Mostly PositivePublishers
10
Articles
6
Reach
16
